TCG Digital, MSK license PlanQ for radiation oncology

TCG Digital has licensed Memorial Sloan Kettering Cancer Center intellectual property to commercialize PlanQ, an AI-powered workflow and clinical decision support platform for radiation oncology. The partnership aims to help care teams work from a shared, real-time view of treatment data and improve reliability and efficiency in radiotherapy delivery.

Why it matters: - Radiation oncology teams often work across fragmented clinical and operational systems. - PlanQ is meant to give care teams a shared, up-to-date view of each patient’s treatment journey. - TCG Digital says the platform is designed to help teams act faster and support improved patient outcomes. - The commercialization effort combines MSK’s clinical innovation with TCG Digital’s AI and platform engineering.

What happened: - TCG Digital licensed intellectual property and knowhow from Memorial Sloan Kettering Cancer Center to develop and commercialize PlanQ. - PlanQ is an AI-powered clinical intelligence platform focused on radiation oncology. - The announcement was issued July 21, 2026. - mcube, TCG Digital’s Enterprise & Agentic AI Platform, will serve as the foundation for PlanQ’s commercialization, scalability and future evolution.

The details: - PlanQ is described as a differentiated workflow system to support clinical decisions in radiation oncology. - The platform is intended to improve the reliability and efficiency of radiotherapy delivery. - mcube combines advanced AI, semantic intelligence, knowledge-driven reasoning, workflow automation and scalable cloud architecture. - Dr. Joseph Deasy, chair of the Department of Medical Physics at MSK, said PlanQ was developed by MSK’s Department of Medical Physics to help radiotherapy teams stay aligned through real-time integration and visualization of patient treatment data. - Dr. Deasy said the platform gives the entire care team a shared, up-to-date view of each patient’s treatment journey. - Dr. Deasy said TCG Digital and MSK are collaborating to bring PlanQ to oncology providers around the globe. - Debdas Sen, CEO of TCG Digital, said the company believes the collaboration can create a next-gen clinical intelligence platform shaped by real-world clinical workflows and operational needs. - TCG Digital says the effort is strengthened by TCG CREST CARE’s cancer research capabilities within the broader TCG ecosystem.

Between the lines: - The deal signals a push to turn clinical research assets into a commercial AI product for oncology providers. - The emphasis on workflow integration suggests PlanQ is aimed as much at operational coordination as at clinical insight. - The partnership also positions TCG Digital to expand deeper into healthcare AI with a product anchored in a major cancer center’s expertise.

What's next: - TCG Digital plans to commercialize PlanQ for oncology providers worldwide. - The platform is expected to evolve on mcube as the company expands its capabilities. - TCG Digital is positioning the product around clinical rigor, patient safety and operational excellence as adoption develops.

The bottom line: - TCG Digital is using MSK-derived IP and its own AI stack to try to build a radiation oncology decision-support platform with real-world clinical utility. - The bet is that better integration of treatment data can make radiotherapy delivery more reliable and efficient.